Literature DB >> 20014119

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.

Katherine A Rauen1, Lisa Schoyer, Frank McCormick, Angela E Lin, Judith E Allanson, David A Stevenson, Karen W Gripp, Giovanni Neri, John C Carey, Eric Legius, Marco Tartaglia, Suzanne Schubbert, Amy E Roberts, Bruce D Gelb, Kevin Shannon, David H Gutmann, Martin McMahon, Carmen Guerra, James A Fagin, Benjamin Yu, Yoko Aoki, Benjamin G Neel, Allan Balmain, Richard R Drake, Garry P Nolan, Martin Zenker, Gideon Bollag, Judith Sebolt-Leopold, Jackson B Gibbs, Alcino J Silva, E Elizabeth Patton, David H Viskochil, Mark W Kieran, Bruce R Korf, Randi J Hagerman, Roger J Packer, Teri Melese.   

Abstract

The RASopathies are a group of genetic syndromes caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Some of these syndromes are neurofibromatosis type 1, Noonan syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, LEOPARD syndrome and Legius syndrome. Their common underlying pathogenetic mechanism brings about significant overlap in phenotypic features and includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium "Genetic Syndromes of the Ras/MAPK Pathway: From Bedside to Bench and Back" chronicle the timely and typical research symposium which brought together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras syndromes and their families. The goals, to discuss basic science and clinical issues, to set forth a solid framework for future research, to direct translational applications towards therapy and to set forth best practices for individuals with RASopathies were successfully meet with a commitment to begin to move towards clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014119      PMCID: PMC4051786          DOI: 10.1002/ajmg.a.33183

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

Review 1.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

  1 in total
  34 in total

1.  Shifting the paradigm for autism treatments.

Authors:  Randi J Hagerman; Robert L Hendren
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

3.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

4.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

Review 5.  The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.

Authors:  Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

6.  New Genetic Insights into Congenital Heart Disease.

Authors:  Stephanie M Ware; John Lynn Jefferies
Journal:  J Clin Exp Cardiolog       Date:  2012-06-15

7.  Functional divergence caused by mutations in an energetic hotspot in ERK2.

Authors:  Clinton A Taylor; Kevin W Cormier; Shannon E Keenan; Svetlana Earnest; Steve Stippec; Chonlarat Wichaidit; Yu-Chi Juang; Junmei Wang; Stanislav Y Shvartsman; Elizabeth J Goldsmith; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

8.  Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.

Authors:  Brian K Stansfield; Waylan K Bessler; Raghuveer Mali; Julie A Mund; Brandon D Downing; Reuben Kapur; David A Ingram
Journal:  Am J Pathol       Date:  2013-11-07       Impact factor: 4.307

9.  Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation.

Authors:  Robert M Harmon; Cory L Simpson; Jodi L Johnson; Jennifer L Koetsier; Adi D Dubash; Nicole A Najor; Ofer Sarig; Eli Sprecher; Kathleen J Green
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

Review 10.  The RASopathies.

Authors:  Katherine A Rauen
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.